At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 393 enrolled
Drug / intervention
Dupilumab SAR231893 (REGN668)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Open-label, Interventional, Cohort Study to Evaluate Long-term Safety of Dupilumab in Patients With Moderate to Severe Asthma Who Completed the TRAVERSE-LTS12551 Clinical Trial
In Brief
A Phase 3 clinical trial evaluating Dupilumab SAR231893 (REGN668) for Asthma. Completed, enrolled 393 participants across 132 sites in 10 countries.
Detailed Summary
Primary Objective: To describe the long-term safety of dupilumab in treatment of participants with moderate to severe asthma who completed the previous asthma clinical trial (TRAVERSE-LTS12551).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesArgentina, Belgium, Canada, France, Germany, Israel, Japan, Netherlands, South Africa, United States
CollaboratorsRegeneron Pharmaceuticals
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartAug 2018
Primary CompletionFeb 2022
TodayJul 2026
First PostedAug 8, 2018
Enrollment StartAug 30, 2018
Primary CompletionFeb 18, 2022
TodayJul 2, 2026
Enrollment to primary: 3.5 yearsPosted 7.9 years ago
Interventions
Dupilumab SAR231893 (REGN668)drug
Pharmaceutical form: prefilled syringes Route of administration: subcutaneous